Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 1079 clinical trials
Effects of Brain Stimulation on Cognition Oscillations and GABA Levels in Schizophrenia

This study has three main goals: (1) To compare the effects of task-engaged versus resting tDCS in order to optimize the impact of tDCS on goal maintenance related neural oscillatory activity and task performance in schizophrenia; (2) To establish the regional specificity of the impact of DLPFC tDCS (compared to …

antipsychotics
transcranial direct current stimulation
brain stimulation
clozapine
schizoaffective disorder
  • 0 views
  • 19 Feb, 2024
  • 1 location
The Potential Added Value of Impulse Oscillometry in Asthma Monitoring (AM-IOS)

Is there a difference in the change in IOS parameters and FEV1 respectively, stratified according to change in other questionnaire such as the asthma control questionnaire and the asthma quality of life questionnaire.Are the proposed minimal clinically important differences (MCIDs) valid for short follow-up periods (3 - 6 months)?

  • 0 views
  • 24 Nov, 2025
  • 1 location
Nivolumab Ipilimumab and Chemoradiation in Treating Patients With Locally Advanced Pancreatic Cancer.

A locally unresectable tumor (locally advanced pancreatic cancer (LAPC)) is present in 30% of the cases and is defined as a surgically unresectable tumor encasing the adjacent arteries [celiac axis, superior mesenteric artery (SMA)]. In these patients, chemotherapy has been the standard treatment for decades, optionally combined with radiotherapy.

serum bilirubin level
pdac
gilbert's syndrome
immunosuppressive agents
platelet count
  • 0 views
  • 24 Nov, 2025
  • 1 location
Changing the Culture of Disrespect and Abuse in Maternity Care in Kumasi Ghana

Based on data collected, feasibility will be examined and the RMC-M will be further modified as needed prior to beginning Aim 2. To achieve Aim 2, a two group study design will be used, with one group of midwives receiving training on the RMC- M and the other not receiving …

prenatal
maternity
  • 0 views
  • 19 Feb, 2024
  • 1 location
SBRT for Breast Cancer Oligometastases

If functional imaging (bone scan, PET) were used at staging, changes in the uptake will be used in follow up scans to determine response to treatment and progression. As for SBRT related morbidities, we will use the Common Terminology Criteria for Adverse Events (CTCAE v5) for toxicity reporting and scoring.

solid tumor
breast cancer
breast neoplasm malignant female
cancer
bone metastases
  • 0 views
  • 19 Feb, 2024
  • 1 location
CCCG Relapsed Acute Lymphoblastic Leukemia 2017 Study in Children

Six doses of rituximab and will be monitored the week 5 MRD and relapse rate as study outcome. Adding bortezomid during the consolidation:The very early or early bone marrow relapse has low remission rate.

flow cytometry
cns involvement
bortezomib injection
rituximab
proteasome inhibitor
  • 0 views
  • 19 Feb, 2024
  • 1 location
Morphological Parameters of In-stent RESTenosis Assessed and Identified by OCT

The number and clinical lifespan of stents implanted over the last twenty-five years, however, explain the fact that restenosis remains a not unusual clinical problem which is expressed as a recurrence of angina or of an acute coronary syndrome (ACS). The mechanisms involved in this restenosis are multifactorial in nature …

  • 0 views
  • 19 Feb, 2024
  • 1 location
Carotid Doppler and EEOT for Fluid Responsiveness Prediction

New approaches have been recently developed based on changes in respiratory dynamics, such as a transient increase in tidal volume, or a lung recruitment maneuver or an end-expiratory occlusion (EEO) test. The EEO leaded to an increase in venous return, cardiac preload and stroke volume in preload-responsive patients.

stroke
  • 0 views
  • 19 Feb, 2024
  • 1 location
1 march 4  

The dose of 1-5 x 10xE8 T-cells in Stage 2 will be administered via split dosing: 10% on Day 1 (1-5x10xE7), 30% on Day 2 (3x107-1.5x10xE8), 60% on Day 3 (6x107-3x10xE8). Evaluable subjects are defined as those who were able to receive the viable product at the intended dose level …

  • 0 views
  • 19 Feb, 2024
  • 1 location
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms

Around 132 participants will be enrolled in approximately 30 sites worldwide. Risankizumab and ustekinumab are given as a subcutaneous (under the skin) injection. Parts 1, 3, and 4: Risankizumab for 40 weeks with a follow-up call 20 weeks later for a study duration of approximately 65 weeks.

systemic therapy
inflammatory disease
plaque psoriasis
psoriasis
ustekinumab
  • 0 views
  • 19 Feb, 2024
  • 9 locations